PTC Therapeutics down 5% after hours as product sales growth remains modest

PTC Therapeutics (NASDAQ:PTCT) Q4 results:

Revenues: $96.5M (+11.8%); Translarna sales: $48.4M (-13.6%); Emflaza sales: $32.7M (+9.7%).

Net loss: ($77.7M); loss/share: ($1.37).

2020 guidance: DMD franchise revenue: $320M – 340M.

Shares down 5% after hours.

PTC Therapeutics EPS misses by $0.88, beats on revenue

https://seekingalpha.com/news/3547733-ptc-therapeutics-down-5-after-hours-product-sales-growth-remains-modest